The Omicron Variant Is Highlighting The Flaws Of China’s Zero-Covid Strategy

Contrary to what Chinese authorities want their residents to believe, the highly transmissible Omicron variant is putting China’s zero-Covid strategy to the test — and it seems to be failing. The number of infections in Shanghai, the country’s financial capital, has been breaching all-time records, with 21,000 new cases just on Friday alone.

The overwhelming spread of the virus has put the city in an indefinite lockdown with much of its 25 million residents unprepared. People are running out of food and ways to get it with delivery services limited, many needing medicine they’re not allowed to go out to get, with some — including children a few months old, and the ailing elderly — forced to be separated from their caregivers.

And yet, the virus keeps spreading.

China’s zero-Covid strategy has been one of the world’s most stringent and effective, at least in the first waves of the pandemic. Its goal is to stamp out transmission through mass testing, aggressive contact-tracing, immediate isolation of infected people, and quarantine of their close contacts. The strategy reduced the country’s transmission rate to near zero, and kept its reported death rate much lower than other developed countries.

But the Omicron surge is another story, and the lockdowns are proving obsolete. China continues to fumble in an attempt to contain a variant that has caused, and is still causing record-breaking surges across the world, instead of focusing on managing its inevitable impact.

In a commentary posted on Facebook, Ho Ching, spouse of Singapore Prime Minister Lee Hsien Loong, underscored the inefficiencies of this strategy, and called for China to instead focus on vaccinations.

The country’s choice of vaccines appears to be more political than anything else. Prime Minister Xi Jinping, in his aggressive bid to champion self-reliance, has kept mRNA vaccines from the West out of China. And because the country itself has yet to develop their own mRNA shot over two years into the pandemic, its residents have had to rely on the two homegrown vaccines, SinoVac and Sinopharm, that both use a century-old method for inoculation. The efficacy of these two brands have been in question, and officials have acknowledged their low overall effectiveness.

China’s continued resistance to Western vaccines is compounded by its low vaccination rate of the elderly. Before the Omicron surge, about 65% of its population over 80 had yet to be inoculated.

Many residents have taken to social media to share their pleas. Some reports say that the country’s internet watchdog, Cyberspace Administration of China, has started scrubbing negative posts off social media. They have also told people to be wary and “distinguish rumours from facts.”


Information for this briefing was found via Bloomberg, Twitter and the sources mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Critical Minerals Strategy Key to US Military Readiness, Pentagon Says

The Department of Defense is intensifying efforts to secure critical minerals essential for military systems,...

Monday, January 13, 2025, 10:14:00 AM

Gold Hits Record as China Launches Insurer Pilot Program

Gold prices reached an all-time high of $2,941 per ounce on Tuesday as China began...

Tuesday, February 11, 2025, 02:10:00 PM

Zoltan Pozsar: G7 Investors Should Worry About Gold-Backed Renminbi Eclipsing Dollars, Commodity Encumbrance

Credit Suisse contributor Zoltan Pozsar has continued his ongoing series about Bretton Woods III where commodities will...

Thursday, December 29, 2022, 08:24:47 AM

Ventripoint Sees First Commercial Sales In China Through Joint Venture

Ventripoint Diagnostics (TSXV: VPT) this morning issued a brief press release related to its joint...

Tuesday, March 2, 2021, 08:25:53 AM

Cobalt Prices Under Pressure from Surging Chinese Output

The cobalt market is facing oversupply issues that could further depress prices through the second...

Thursday, April 25, 2024, 12:27:27 PM